Gender | Male/Female | 13/6 |
Age (year) | Mean ± SD | 66.2 ± 10.1 |
Range | 44 - 86 | |
ECOG-PS | 0/1 | 19/0 |
Surgery | Lobectomy | 19 |
Histology | Adenocarcinoma | 17 |
Squamous cell carcinoma | 2 | |
Pathological stage | IIA | 2 |
IIIA | 9 | |
IIIB | 3 | |
IV | 5 | |
Chemotherapy | Neoadjuvant therapy | 3 |
Adjuvant therapy | 11 | |
Intensive chemotherapy for recurrence | 5 | |
Regimen | GEM + CBDCA | 13 |
PTX + CBDCA | 3 | |
DOC + CDDP | 2 | |
DOC | 1 | |
Planned cycles | 2/3/4 cycles | 8/3/8 |
Received cycles | 2/3/4 cycles | 8/3/8 |
Compliance | Dose reduction | 5/19 (26.3%) |
Delayed | 1/19 (5.3%) | |
Response evaluation | Partial response | 3 (37.5%, 3/8) |
Stable disease | 5 (62.5%, 5/8) | |
Toxicities | ≥Grade 3/4 | 14/19 (73.7%) |